290 related articles for article (PubMed ID: 34321846)
1. Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics.
Di Sessa A; Riccio S; Pirozzi E; Verde M; Passaro AP; Umano GR; Guarino S; Miraglia Del Giudice E; Marzuillo P
World J Gastroenterol; 2021 Jul; 27(25):3815-3824. PubMed ID: 34321846
[TBL] [Abstract][Full Text] [Related]
2. Concise review of lipidomics in nonalcoholic fatty liver disease.
Béland-Bonenfant S; Rouland A; Petit JM; Vergès B
Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065
[TBL] [Abstract][Full Text] [Related]
3. Update on lipid species and paediatric nonalcoholic fatty liver disease.
Mann JP; Feldstein AE; Nobili V
Curr Opin Clin Nutr Metab Care; 2017 Mar; 20(2):110-116. PubMed ID: 27906700
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease.
Deng KQ; Huang X; Lei F; Zhang XJ; Zhang P; She ZG; Cai J; Ji YX; Li H
Am J Physiol Cell Physiol; 2022 Aug; 323(2):C630-C639. PubMed ID: 35759443
[TBL] [Abstract][Full Text] [Related]
5. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
[TBL] [Abstract][Full Text] [Related]
6. Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.
Riccio S; Melone R; Vitulano C; Guida P; Maddaluno I; Guarino S; Marzuillo P; Miraglia Del Giudice E; Di Sessa A
World J Clin Pediatr; 2022 May; 11(3):221-238. PubMed ID: 35663007
[TBL] [Abstract][Full Text] [Related]
7. Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease.
Draijer LG; Froon-Torenstra D; van Weeghel M; Vaz FM; Bohte AE; Holleboom AG; Benninga MA; Koot BGP
J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):433-439. PubMed ID: 32947564
[TBL] [Abstract][Full Text] [Related]
8. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).
Mocciaro G; Allison M; Jenkins B; Azzu V; Huang-Doran I; Herrera-Marcos LV; Hall Z; Murgia A; Susan D; Frontini M; Vidal-Puig A; Koulman A; Griffin JL; Vacca M
Mol Metab; 2023 Jul; 73():101728. PubMed ID: 37084865
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model".
Fang YL; Chen H; Wang CL; Liang L
World J Gastroenterol; 2018 Jul; 24(27):2974-2983. PubMed ID: 30038464
[TBL] [Abstract][Full Text] [Related]
11. Postprandial Plasma Lipidomics Reveal Specific Alteration of Hepatic-derived Diacylglycerols in Nonalcoholic Fatty Liver Disease.
Velenosi TJ; Ben-Yakov G; Podszun MC; Hercun J; Etzion O; Yang S; Nadal C; Haynes-Williams V; Huang WA; González-Hódar L; Brychta RJ; Takahashi S; Akkaraju V; Krausz KW; Walter M; Cai H; Walter PJ; Muniyappa R; Chen KY; Gonzalez FJ; Rotman Y
Gastroenterology; 2022 Jun; 162(7):1990-2003. PubMed ID: 35283114
[TBL] [Abstract][Full Text] [Related]
12. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
[TBL] [Abstract][Full Text] [Related]
13. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
14. Metabolic aspects of adult patients with nonalcoholic fatty liver disease.
Abenavoli L; Milic N; Di Renzo L; Preveden T; Medić-Stojanoska M; De Lorenzo A
World J Gastroenterol; 2016 Aug; 22(31):7006-16. PubMed ID: 27610012
[TBL] [Abstract][Full Text] [Related]
15. Lipidomics in non-alcoholic fatty liver disease.
Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.
Peng KY; Watt MJ; Rensen S; Greve JW; Huynh K; Jayawardana KS; Meikle PJ; Meex RCR
J Lipid Res; 2018 Oct; 59(10):1977-1986. PubMed ID: 30042157
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity.
Peng L; Wu S; Zhou N; Zhu S; Liu Q; Li X
BMC Pediatr; 2021 Mar; 21(1):122. PubMed ID: 33711964
[TBL] [Abstract][Full Text] [Related]
19. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Arab JP; Arrese M; Trauner M
Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
[TBL] [Abstract][Full Text] [Related]
20. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats.
Deng Y; Pan M; Nie H; Zheng C; Tang K; Zhang Y; Yang Q
Molecules; 2019 Oct; 24(21):. PubMed ID: 31683679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
